Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

UROKINASE-GREEN CROSS INJ. 60,000 IU/VIAL [SIN11140P]

Active ingredients: UROKINASE

View product's general information
Last updated on 9 October 2026

Product Info

UROKINASE-GREEN CROSS INJ. 60,000 IU/VIAL

[SIN11140P]

Product information

Active Ingredient and Strength

UROKINASE - 60,000 INTERNATIONAL UNITS/VIAL

Dosage Form

INJECTION, POWDER, FOR SOLUTION

Manufacturer and Country

CHINA CHEMICAL & PHARMACEUTICAL CO., LTD. - TAIWAN

Registration Number

SIN11140P

Licence Holder

GRIFOLS ASIA PACIFIC PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

B01AD04

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

INDICATIONS
Treatment of the following thrombotic-occlusive diseases:
♦ Cerebral thrombosis (within 5 days after the onset of symptoms, and without hemorrhage detectable by computed tomography)
♦ Peripheral arterial-venous occlusion (within 10 days after the onset of symptoms)

Dosing

DOSAGE AND ADMINISTRATION
Reconstitute the contents of one vial with 10 mL of physiological saline and inject intravenously. Preferably instill as an admixture with physiological saline or glucose injection.

[Thrombotic-occulsive diseases]
♦ Cerebral thrombosis: Administer 60,000 international units once a day for about 7 days.
♦ Peripheral arterial-venous occlusion: Administer 60,000 to 240,000 international units on first day of treatment followed by tapered doses for about 7 days.

Contraindications

(2) Contraindications

  1. Patients for whom hemostatic management is difficult: intracranial hemorrhage, hemoptysis, retroperitoneal hemorrhage and the like.

  2. Patients having undergone intracranial or spinal surgery or with such injury (in the last 2 months).

  3. Patients with aneurysm.

  4. Patients with serious disturbances of consciousness.

(3) Contraindications as a general rule
This product is contraindicated in the following patients, as a general rule. If essential, however, it can be administered with caution.

  1. Patients with atrial fibrillation (particularly with mitral stenosis), patients with infective endocarditis, patients with old myocardial infarction, and patients with a prosthetic valve.

  2. Patients with neurological signs and symptoms of stroke which became complete instantaneously.